SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5159.05M
Enterprise Value 3-33.85M
Trailing P/E N/A
Forward P/E 1-2.20
PEG Ratio (5 yr expected) 1-0.01
Price/Sales (ttm)N/A
Price/Book (mrq)0.49
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 60.60

Trading Information

Stock Price History

Beta (5Y Monthly) 1.30
52-Week Change 3-78.15%
S&P500 52-Week Change 320.64%
52 Week High 380.40
52 Week Low 38.64
50-Day Moving Average 314.64
200-Day Moving Average 314.75

Share Statistics

Avg Vol (3 month) 373.03k
Avg Vol (10 day) 385.06k
Shares Outstanding 510.4M
Float 1.18M
% Held by Insiders 12.83%
% Held by Institutions 131.48%
Shares Short (Jan 30, 2020) 4152.17k
Short Ratio (Jan 30, 2020) 42.54
Short % of Float (Jan 30, 2020) 49.26%
Short % of Shares Outstanding (Jan 30, 2020) 48.15%
Shares Short (prior month Dec 30, 2019) 4137.85k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:40
Last Split Date 3Jan 22, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-36.86%
Return on Equity (ttm)-66.41%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -56.51M
Net Income Avi to Common (ttm)-55.1M
Diluted EPS (ttm)-29.56
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)67.69M
Total Cash Per Share (mrq)36.25
Total Debt (mrq)5.61M
Total Debt/Equity (mrq)9.53
Current Ratio (mrq)7.69
Book Value Per Share (mrq)31.52

Cash Flow Statement

Operating Cash Flow (ttm)-48.7M
Levered Free Cash Flow (ttm)-29.39M